REVIEW

Tissue-resident lymphocytes: weaponized sentinels at barrier surfaces [version 1; peer review: 3 approved]

Gabrielle T. Belz ¹⁻³, Renae Denman ¹, Cyril Seillet^{2,3}, Nicolas Jacquelot ^{2,3}

¹The University of Queensland, Diamantina Institute, Brisbane, Queensland, 4102, Australia

²Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria, 3052, Australia

³Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, 3010, Australia

V1 First published: 09 Jul 2020, 9(Faculty Rev):691
<https://doi.org/10.12688/f1000research.25234.1>

Latest published: 09 Jul 2020, 9(Faculty Rev):691
<https://doi.org/10.12688/f1000research.25234.1>

Abstract

Tissue-resident immune cells stably localize in tissues largely independent of the circulatory system. While initial studies have focused on the recognition of CD8⁺ tissue-resident memory T (CD8 T_{RM}) cells, it is now clear that numerous cell types such as CD4⁺ T cells, gd T cells, innate lymphoid cells and mucosal-associated invariant T (MAIT) cells form stable populations in tissues. They are enriched at the barrier surfaces and within non-lymphoid compartments. They provide an extensive immune network capable of sensing local perturbations of the body's homeostasis. This positioning enables immune cells to positively influence immune protection against infection and cancer but paradoxically also augment autoimmunity, allergy and chronic inflammatory diseases. Here, we highlight the recent studies across multiple lymphoid immune cell types that have emerged on this research topic and extend our understanding of this important cellular network. In addition, we highlight the areas that remain gaps in our knowledge of the regulation of these cells and how a deeper understanding may result in new ways to 'target' these cells to influence disease outcome and treatments.

Keywords

memory T cells, tissue-resident cells, immune protection, barrier protection, pathogens

Open Peer Review

Approval Status

	1	2	3
version 1 09 Jul 2020			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Richard M. Locksley**, University of California, San Francisco, USA
2. **Kingston Mills**, Trinity College Dublin, Dublin, Ireland
3. **Jeffrey C. Nolz**, Oregon Health & Science University, Portland, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Gabrielle T. Belz (g.belz@uq.edu.au)

Author roles: **Belz GT:** Conceptualization, Funding Acquisition, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Denman R:** Writing – Original Draft Preparation, Writing – Review & Editing; **Seillet C:** Writing – Original Draft Preparation, Writing – Review & Editing; **Jacquelot N:** Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by grants (1122277 and 1054925 to GTB, and 1165443 to GTB and CS) and fellowships (1135898 to GTB and 1123000 to CS) from the National Health and Medical Research Council and support from the Cure Cancer Australia and Cancer Australia Priority-driven Cancer Research Scheme (1163990 to NJ).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Belz GT *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Belz GT, Denman R, Seillet C and Jacquelot N. **Tissue-resident lymphocytes: weaponized sentinels at barrier surfaces [version 1; peer review: 3 approved]** F1000Research 2020, 9(Faculty Rev):691 <https://doi.org/10.12688/f1000research.25234.1>

First published: 09 Jul 2020, 9(Faculty Rev):691 <https://doi.org/10.12688/f1000research.25234.1>

Introduction

The immune system is composed of millions of diverse cell types distributed amongst the circulatory systems and the tissues. Immune cells found in the blood and lymphoid tissues are the primary anatomic compartments that have been studied and form the foundation of our understanding of immune cell homeostasis. Indeed, recirculation of memory T cells is a hallmark of their functional capacity to affect their protective roles during immunosurveillance. Despite this, the vast majority of immune cells are not located in the circulation trafficking between the lymphoid tissues and blood or lymph. Instead, they are localized in non-lymphoid tissues where they can reside for extensive periods of time. The significant concentration of immune cells within the barrier tissues—the skin and digestive, reproductive and respiratory tracts—pivotal positions antigen-experienced cells to mediate local responses against antigenic and pathogenic challenges. The identification of ‘tissue-resident’ T cells resolved a major problem in the immune system by positioning ‘primed’ cytolytic cells in tissue compartments where they would first encounter a pathogen or breach the body’s surface.

But is tissue residency limited to CD8⁺ T cells? Despite the attraction of such a thesis, there is little evidence that this type of programming should be restricted to a single-cell subset when the immune system is colonized by a myriad of diverse cells, many of which occur at mucosal or barrier surfaces. If the program is broader, how is it regulated and is it fixed such that immune cells are predestined to a tissue-resident fate? Or is there plasticity in the system enabling resident cells to become mobile, and for mobile cells to change tactics and become sedentary?

Multiple cell types are now recognized to be highly enriched at the body’s barrier surfaces and in non-lymphoid tissues. This includes classic adaptive thymic-derived conventional and regulatory CD4⁺ and CD8⁺ T-cell subsets together with different subsets of innate immune cells and so-called non-conventional lymphocytes such as $\gamma\delta$ T cells, natural killer (NK) T cells, mucosal-associated invariant T (MAIT) cells and CD8 $\alpha\alpha$ intra-epithelial lymphocytes. Our understanding of these different cell types is beyond the scope of this review but they provide important clues in understanding immune system recognition of antigenic types and how border protection might have evolved evolutionarily. Indeed, the emergence of the discoveries and functions around these diverse cell types opens the door to unexpected targeting approaches to temporally regulate immune cell subtypes and provide new strategies for harnessing control of infectious agents and elimination of tumor cells.

Recent studies have uncovered a number of the mechanisms that regulate the temporal positioning of tissue-resident cells, but they have also revealed unexpected cues such as sensory detection and stromal cell signals which set the threshold for the transition of tissue-resident cell retention within local tissues where they are focused on local responses and remodelling to systemic responses affecting distant organs.

CD8⁺ T-cell tissue residency: rethinking immune cell lifestyles

The initial description of ‘tissue-resident’ T cells was based on the identification of specific markers that were deemed to reflect stable positioning in tissues (CD103, CD49a and CD69) and the lack of molecules associated with tissue egress and migration to secondary lymphoid organs (Klf2, S1Pr1, CCR7 and CD62L) (Figure 1). The localization of tissue-resident memory cells within tissues, particularly at barrier surfaces, theoretically positions them to be able to initiate a faster immune response towards a pathogen without the necessity to engage other immune or stromal cells¹. The notion is that resident cells can undergo extensive proliferation within the tissues, allowing them to replenish, but that they do not appear to accumulate, remaining numerically stable over time^{2–4}. This concept is supported by the failure to detect significant movement of cells within a tissue in stark contrast to effector memory T cells that are found largely in the blood and patrol the body^{2,5–7}. Recent evidence indicates that tissue preparation approaches greatly influence the detection of ‘tissue-resident’ cells, significantly underestimating their prevalence⁸. Furthermore, in peripheral sites, many T cells did not express CD103 or CD69, indicating that these molecules are not universal markers and their expression reflects site-specific characteristics⁸. It also highlights that these other T-cell populations exist in these sites and are likely to play an important role in rapid responses to secondary challenges. T cell analyses based on CX3CR1 expression revealed that effector memory (T_{EM}) cells (CX3CR1⁺) themselves are largely excluded from tissues while central memory (T_{CM}) cells and CX3CR1^{intermediate} cells homed to lymph nodes but that CX3CR1^{intermediate} cells were the dominant cell surveying peripheral tissues⁹. Furthermore, central memory cells are enabled to migrate to non-lymphoid tissues and form the predominant population in these tissues following inflammation¹⁰. This capability results from induction of the expression of E- and P-selectins due to interleukin (IL)-15-stimulated enzymatic synthesis of core 2 O-glycans that regulate CD8⁺ T-cell migratory behaviour¹⁰. These studies highlight that tissue residency is not a static state for T cells or even other lymphocyte subsets.

Tissue-resident memory T (T_{RM}) cells within peripheral tissues can not only mobilize to adjacent tissues but can also re-join the circulating memory T cell masses to maintain a stable equilibrium. Indeed, Fonseca *et al.*¹¹ recently examined this in detail and demonstrated that small intestinal tissue-resident memory cells could re-enter the circulating pool of cells and exhibited the capacity to differentiate into effector and central memory cells. Although these memory cells contribute to the overall pool of T cells, they exhibit a predilection for homing back to the tissue of origin following reactivation consistent with very early studies in the field that showed a similar phenomenon in which distinct immune cell subsets display restricted and often tissue-selective patterns of recirculation¹². Thus, tissue-resident lymphocytes are distinctive by their location in non-lymphoid tissues but do appear able to undergo

Figure 1. Tissue residency and modulation across lymphoid subsets and tissues. Effector T cells enter peripheral and non-lymphoid tissues and establish themselves as non-recirculating tissue-resident memory T (T_{RM}) cells. Transforming growth factor-beta ($TGF-\beta$) and Hobit act as master regulators of tissue residency and regulate the expression of CD103, CD69 and CD49a of tissue-resident cells such as innate lymphoid cell 1 (ILC1) and T_{RM} cells. Natural killer (NK) cells appear to continuously circulate around the body. In the presence of $TGF-\beta$, NK cells can transdifferentiate into ILC1-like cells. ILC1, 2 and 3 are generally non-circulating and establish in tissues. Their activity is intimately modulated by numerous tissue-related factors. These include neuropeptides such as vasoactive intestinal peptide (VIP) and neuromedin U (NMU) that can activate (+) or inhibit (–) cytokine secretion. In response to an immunological threat, T cells and ILCs can relatively readily become mobile and exit tissues via the lymphatics to join circulating immune cells. Nevertheless, these cells exhibit a preference for returning to their 'tissue of origin' when they re-establish tissue residency. IL, interleukin.

some recirculation through a tightly regulated chemokine receptor and integrin expression pattern.

In this recent work examining the distribution of T cells in mice¹¹ and NK cells in humans¹³, tissue-resident cells exhibited a less activated phenotype compared with their more centrally deployed counterparts and this has led to the notion of 'outside-in' activation¹¹. Studying the behaviour of immune cells in the face of the onslaught by an invading pathogen trying to kill us brings our attention into sharp focus on the armoury of effector molecules used to mitigate a pathogen invasion. This, it would seem, is a rather artificial situation, however, as it reflects a last-ditch effort by the innate and adaptive immune system to fight back. It is much more greatly appreciated now, though, that disease is a relatively rare state—an organism's health depends on the maintenance of day-to-day homeostasis. Accompanying this is the very tight regulation of effector responses in tissue-resident cells and more subtle expression profiles of a number of molecules^{11,13}. The checks-and-balances by molecular regulators within the tissues, immune cells and non-immune cells, such as neurons, physiologically integrate signals that implement activation and simultaneously restrict the development of immunopathology.

To date, our understanding of these tissue signals are not well characterised, and they are of significant interest in understanding how barrier immune health is maintained.

Lung-resident memory T cells

Lung-resident memory T cells are important to delay the spread of pathogens and recruiting recirculating T_{EM} cells. They are known to play a vital role in mounting protection against respiratory viral, bacterial and parasitic infections, including influenza virus¹⁴, coronaviruses such as SARS-CoV and MERS-CoV^{15,16}, *Bordetella pertussis*¹⁷ and *Nippostrongylus brasiliensis*^{18,19}. T_{RM} cells expand during infection and specifically target infected cells¹⁷. In some cases, this response eliminates the virus and drives resolution of the illness but, in the case of influenza and coronaviruses, can lead to highly vigorous responses that induce severe pathology and may be lethal. In the lungs, T_{RM} cell populations include $CD8^+ T_{RM}$, $CD4^+ T_{RM}$ and regulatory T (T_{reg}) cells. $CD8^+ T_{RM}$ cells are found in the epithelial layer of the airways and the lung parenchyma involved in gas exchange^{1,20}. However, the main cell type that affords protection in the lung parenchyma is the $CD4^+ T_{RM}$ cell both following lung infection and in providing protection in vaccine models^{1,14,15,17,19,21–23}. $CD8^+ T_{RM}$ cells have also been

identified as a useful target for vaccines. CD8⁺ T_{RM} cells located in the lung parenchyma are a more appropriate target for vaccine strategies as epithelial T_{RM} cells are short-lived and the capacity to develop new niches for this cell population is important prior to vaccination^{20,21,24,25}. Following lung injury, CD8⁺ T_{RM} cells have been found to localize in niches where tissue regeneration has occurred and have been referred to as repair-associated memory depots²⁰. CD4⁺ T_{RM} cells, however, localize to the airways or around B-cell follicles and form clusters in inducible bronchus-associated lymphoid tissue (iBALT) where they can affect long-term immune protection^{20,26}.

Lung CD4⁺ T_{RM} cells have been shown to be maintained at constant numbers over time following allergen exposure^{26,27}. They have also been found to expand in the lungs during *B. pertussis* infection and more rapidly after reinfection^{17,28}. In contrast, CD8⁺ T_{RM} cell populations appear to wane over time^{24,29}. Thus, CD8⁺ T_{RM} cells in the epithelium of the airways must be replenished from recirculating T_{EM} cells²⁹ or from CD8⁺ T_{RM} cells in the lung parenchyma²⁰. This is likely due to a process in the lungs where tissue-resident cells in the epithelium are continuously cleared by phagocytic cells or via mucociliary clearance²⁹. In the case of respiratory infections such as influenza and respiratory syncytial virus, this might explain in part why complete protection is not afforded in individuals with secondary infection²⁴. T_{reg} cells in the lungs have been found to permanently reside in tissues. This has been confirmed by their expression of CD69 and CD103, which are markers of tissue residency³⁰. CD103 (αE), an integrin protein encoded by the gene *Itgae*, is not simply a marker of tissue residency but can heterodimerize with the integrin beta 7 (β7) to form the molecule αEβ7. This complex confers specificity for binding to E-cadherin and thus acts as a tether for cells in the epithelium, including CD8⁺ T_{RM} cells³¹. Resident T_{reg} cells have been found to protect against lung injury and evidence has shown that they communicate with other tissue-resident cell types that together promote lung homeostasis³⁰. T_{reg} cells are located in iBALT and function by inhibiting B-cell responses, which can be beneficial in cases such as lung transplantation, where they prevent alloimmune responses³². Therefore, lung T_{RM} cells are an important cell type that could be used as a future target for vaccines for respiratory infections.

Transcriptional regulation in tissue-resident T cells

Tissue-resident cells exhibit a number of features that are distinct from their circulating counterparts. The hallmark molecular profile of tissue-resident cells is a shared expression of genes encoding adhesion (*Itga1* and *Itgae*) and immunoregulatory (*Cd244*, *Icos* and *Ctla-4*) molecules together with downregulation of genes required for tissue egress, such as *S1pr1* (which encodes the receptor S1P1 for sphingosine 1-phosphate), which is regulated by Krüppel-like factor 2³³. Indeed, enforced expression of S1PR1 in CD8⁺ T cells results in a phenotype that no longer reflects tissue-resident cells³³. Similarly, downregulation of Eomes (encoded by *Eomesodermin*) and T-bet (encoded by *Tbx21*) expression through transforming growth factor-beta (TGF-β) responsiveness appears necessary to maintain tissue

residency³⁴. This suggests that repression of S1PR1 is essential to the tissue-resident phenotype but also implies that the program is not fixed. Other transcription factors such as Hobit (homolog of B lymphocyte-induced maturation protein, Blimp-1) in T cells (Hobit; also known as *ZFP683*) are not individually required for tissue-resident cells in tissues, but loss of Hobit combined with Blimp-1 (encoded by *Prdm1*), which alone is normally associated with terminal differentiation of CD8⁺ T cells, revealed a more centrally regulated program required by some populations such as tissue-resident cells³⁵, whereas lung-resident cells depended more strongly on Blimp-1³⁶. Precisely how these factors are all regulated is still unclear, particularly in the case of Hobit as expression patterns in humans appear quite different from those in mice^{37,38}. Indeed, detailed analyses of the transcriptome of different T-cell populations that had already encountered antigens demonstrated that the central memory and tissue-resident memory cells exhibited a highly similar epigenetic program and were distinct from recently activated effector cells. This program indicated that cells exhibit considerable plasticity enabling tissue-resident cells to re-join the circulatory pool of CD8⁺ T cells although they were heritably imprinted to favour homing to their originating tissues¹¹.

Most studies that have examined the developmental profile (effector and memory fate decisions) and localization of lymphocytes have been predicated on the notion that the starting point is a relatively homogeneous population for which fate outcomes are defined by stochastic and environmental or external triggers. Although this approach simplifies modeling outcomes, several studies suggest that heterogeneity may reflect the several waves of layering that occur during the developmental distribution of activated fetal-derived cells across different tissues^{39–42}. However, underlying intrinsic programs appear to be already established in fetal cells. Elegant analyses of ‘time stamped’ fetal and adult CD8⁺ T cells highlight this early establishment of diversity which establishes the blueprint from which subsequent tissue-specific shaping in response to environmental and pathogen challenge occurs⁴¹. These temporal fate-mapping approaches combined with extensive single-cell multi-tissue transcriptional analyses in T cells⁴¹, innate lymphoid cells (ILCs)^{39,43} and monocytes⁴⁰ comparing fetal and adult lymphocytes have been critical in uncovering this additional level of complexity. Unfortunately, we do not generally have markers with good resolution to distinguish fetal from adult cells and this will be necessary to comprehensively integrate the many layers of programming that contribute to the effector function and localization properties of protective immune cells.

Tissue residency: not just for adaptive cells

Although the first discovery of tissue residency was uncovered in CD8⁺ T cells^{6,44–47}, non-adaptive immune cells also populate mucosal and peripheral sites following antigen encounter, suggesting that localization of innate cells is necessary for optimal protective immunity to pathogens. NK cells have classically been considered to circulate through the body,

allowing them to patrol tissues and localize and destroy transformed or virally infected cells. However, a very recent global survey of different anatomical sites for human NK cell subsets revealed that these cells exhibit tissue-specific phenotypes and distributions that varied across age, sex and exposure to infection such as cytomegalovirus¹³. Thus, NK cells, like T cells, can also be positioned at the front line for pathogen encounters and the features of these cells are extensively and specifically shaped by their tissue localization. Molecularly, they exhibited transcriptional signatures that included the genes *CCR7*, *SELL*, *CXCR3* and *CCR5* providing post codes for tissue-specific localization and *TCF1* and *LEF1* enabling them to maintain populations at the tissue site through homeostatic proliferation. Thus, in addition to expressing many effector molecules that align NK cells with CD8⁺ T cell function, they have a similar distribution in the body.

Tissue-resident but not immobile

The term 'tissue residency' implies that cells are not mobile. It reflects that cells remain generally confined within a single tissue. However, it is clear that a cell's existence in a tissue is far from static. Conventional NK cells are highly mobile. Other subsets of ILCs or their precursors, however, are distributed to the tissues during the perinatal period where they undergo proliferation and appear to establish in long-term tissue-specific niches, features reflected in their transcriptome³⁹ (Figure 1). Seeding of these tissues depends on a number of receptors, including $\alpha 4\beta 7$ integrin, CXCR5, CXCR6 and (to a lesser extent) CCR7^{43,48–51}. Retention within the tissues themselves is less well understood but is likely to depend on receptors similar to those tethering T cells in tissues such as CD69, which antagonizes the receptors S1PR1⁵², CD49a⁵³ and CD103 (αE integrin)^{54,55}. CD49 expression by T_{RM} cells is indicative of poised cytotoxic function, but CD49a-CD8⁺ T cells have also been identified in healthy human skin and enriched in psoriasis. This latter population is associated with IL-17 production, highlighting the dichotomy in T_{RM} cell function and receptor expression in different settings⁵³. Following from a number of studies, however, was whether ILCs undergo recirculation. Initial studies examining movement of ILCs in parabiont mice and stem cell transplantation models supported the notion that ILCs were mandatorily tissue-resident. Emerging evidence strongly argues otherwise, and although ILCs do not undergo mass migration at steady state, they do indeed respond to various stimuli and rewire their molecular programs to undergo migration^{56,57}. It has been demonstrated that ILC2s particularly are capable of intra-tissue mobility, a critical feature that dictates effective immune responses. Mature ILC2s residing in the gut have been shown to undergo proliferation, lymph node migration and dissemination into the blood in response to activation of alarmins, such as those found during *N. brasiliensis* infection. Migration to diverse tissue sites depends on SIP-mediated chemotaxis, which is also important for NK cells^{58–60}. Thus, local perturbations allow extrusion of ILCs for distribution to distant tissue sites⁶¹. This is in addition to the capacity for ILC2s to exit the bone marrow to replenish tissue pools following IL-33⁶² or fungal aeroallergen challenge⁶³. Similarly, ILC3s exhibit a constant influx and egress

from the cryptopatch during inflammation, a circuitry driven by stromal cell oxysterol activation of the GPR183 receptor^{64–66}. Collectively, these studies highlight that a highly orchestrated receptor expression pattern guides the recruitment and strategic positioning of innate cells in tissues and their deployment to distant sites when local perturbations occur.

Sensory neurons broadcast local tissue perturbations

Recent major studies have highlighted the link between the immune and nervous systems at the mucosal barrier. Both systems can sense cytokines and neurotransmitters, allowing direct communication. For example, receptors for IL-6, TGF- β , IL-1- β and tumor necrosis factor- α (TNF- α) are found in both the brain and enteric neurons^{67–69} while immune cells express receptors for neuropeptides (Figure 1). Several neuropeptides have been described to regulate immune cell activity and maintain tissue homeostasis but also the optimal immune response during infections. ILC2s are important to initiate responses to parasitic infections and allergic reactions that are directly regulated by neuromedin U (NMU)^{70–72}. NMUR1 is specifically expressed on ILC2s and is found in close contact with NMU-expressing cholinergic neurons^{70–72}. NMU is induced during parasitic helminth *N. brasiliensis* infection and directly induces the production of IL-5 and IL-13 by ILC2s. In the absence of NMUR signalling, these type 2 responses are impaired, resulting in poor control of worm infection.

ILC2s are also sensitive to the vasoactive intestinal peptide (VIP), a neurotransmitter expressed in neurons found in the lung and gut⁷³. VIP can stimulate the secretion of IL-5 by lung ILC2s which regulate systemic eosinophil numbers⁷⁴. In turn, lung nociceptors can sense IL-5 released to promote the production of VIP. This inflammatory signalling loop needs to be tightly controlled as dysregulation can lead to the development of allergic inflammation⁷⁵. VIP also regulates the activity of enteric ILC3s and their secretion of IL-22^{76,77}. It variously upregulates⁷⁶ or inhibits⁷⁷ IL-22 production by ILC3s, depending on the study. What is clear, however, is that VIP is induced after ingestion of food and this directly links information from the digestive system to enteric ILC3s driving their function^{76,77}. Dampening the VIP signal to ILC3s increases susceptibility to inflammation-induced gut injuries and infection^{76,77}. This rapid delivery of information is affected by clustering of ILC3s around VIP⁺ neurons providing a mechanism to rapidly influence ILC3 activity⁷⁶.

While the nervous system can sense pathogens to activate immune cells in tissues, it also provides negative feedback loops which act to protect the host by preventing excessive inflammation that could lead to chronic inflammation. For example, beta-adrenergic receptors are activated by norepinephrine that inhibits ILC2 proliferation and function⁷⁸. This mechanism may function as a molecular rheostat to fine-tune the ILC2 response. Vagal nerve activation can modulate the secretion of pro-inflammatory cytokines in macrophages⁷⁹. This in turn leads to a negative regulatory loop which controls inflammation through the release of acetylcholine. Vagal disruption induces a

reduction in the number of ILC3s in the peritoneum and in the protectin biosynthetic pathway, PCTRI⁸⁰. PCTRI is a pro-resolving mediator produced by ILC3s in response to acetylcholine and disruption of this pathway delays the resolution of inflammation associated with infection⁸⁰.

Collectively, these studies highlight the critical crosstalk that occurs between the immune and nervous systems which is necessary to both initiate and control the immune activity during inflammation. Disruption in this crosstalk leads to the development of chronic inflammation or suboptimal immune responses to pathogen infections^{73–78,80}.

Resident innate cells are new potent drivers of tumor protection and immune targeting

Tumor formation results from a lack of detection and/or eradication of transformed cells by immune cells, leading to the progressive emergence of malignant tumors^{81,82}. A combination of host- and tumor-related mechanisms is responsible for the development of neoplasms⁸³. These seminal studies that have built our current view of modern tumor immunology have markedly increased our understanding of tumor immunity, but the underlying models were built on the study of systemic immunity largely neglecting more localized immune cell contributions, particularly those driving early peripheral immunosurveillance. Recent investigations using high-throughput cellular and molecular methods have shed light on the enormous diversity of immune cell types within tissues^{84,85}, including tumors^{86–88}. Critically, this has provided insights into the role of tissue-resident cells demonstrating that tumor-infiltrating CD103-expressing T cells that align to a tissue-resident memory cell phenotype could be found in multiple cancer types^{89–93}. While CD69 and CD103 are commonly used to identify T_{RM} cells, these markers might also be upregulated on activated tumor-infiltrating T-cell subsets in the context of tumors. Thus, it remains unclear whether CD69⁺CD103⁺T cells are true T_{RM} cells or alternately the expression of these molecules identifies effector T-cell subsets that have infiltrated the tumor bed where abundant TGF- β found in a large quantity in many tumors drives CD103 expression. Nevertheless, numerous studies have found a positive association between tumor CD69⁺CD103⁺T-cell infiltration and clinical outcomes, suggesting the beneficial role of this immune cell population in restricting tumor development and therapeutic responses^{86,88,94–98}. In addition, tumor-infiltrating T_{RM} cells express several immune checkpoint molecules (for example, CTLA-4, TIGIT, TIM-3, LAG3 and programmed cell death-1 [PD-1]), indicating that they might respond effectively to immune checkpoint blockers^{86,88,98}. This is highlighted by the association of tumor enrichment of T_{RM} cells, or in genes preferentially expressed by T_{RM} cells, during anti-PD-1 therapy with increased responsiveness to treatment^{88,94,99}. However, despite the expression of immune checkpoint molecules, tumor T_{RM} cells do not seem to harbor an exhausted phenotype and express high levels of IL-2, interferon gamma, TNF- α and cytotoxic molecules⁹⁹. These cells also proliferated more and had reduced T cell receptor diversity compared with non-T_{RM} cells.

In addition, increased clonal expansion was observed which might be associated with the specific recognition of tumor-associated antigens that would drive antigen-specific T_{RM} cell proliferation⁹⁹. However, formal identification of antigen-specific T_{RM} cells through tetramer staining is required to confirm that these cells are not exhausted and are able to secrete a large amount of pro-inflammatory cytokines and cytotoxic molecules upon antigen re-exposure. Collectively, T_{RM} cells represent an emerging and highly valuable immune cell population with potent effector functions important in anti-tumor immunity.

In addition to identifying adaptive resident T lymphocytes, pioneering work has identified tissue-resident ILCs in both murine and human tumors^{100–103}. Our understanding of the characteristics of these cells in the cancer microenvironment is just beginning to emerge. They exhibit both pro- and anti-tumorigenic functions depending on the tissue involved^{100–103}. While tumor-infiltrating NK cells are often associated with a good prognosis, the accumulation of ILC1s that have transdifferentiated from NK cells is correlated with a loss of anti-tumor protection¹⁰⁴. Although immunosuppressive functions have been attributed to ILC2s found in tumors through their production of type 2 cytokines and enhancement of myeloid-derived suppressor cell function¹⁰⁵, the role of these cells in tumor immunity is still fairly limited¹⁰⁶. A recent study demonstrated that ILC2s could induce potent anti-tumor responses in pancreatic cancer and were associated with anti-PD-1 therapy efficacy¹⁰⁷. This elegant work revealed that ILC2s can accumulate in pancreatic tumors and are associated with positive outcomes for patients. IL-33-dependent ILC2 tumor infiltration drove intra-tumoral dendritic cell accumulation, collectively improving anti-tumor immunity. However, IL-33-activated tumor-infiltrating ILC2s expressed PD-1. This normally inhibits their anti-tumor functions but ablation of PD-1 expression, or blocking the interaction with its ligand using monoclonal antibodies, negated this effect and enhanced the anti-tumor response¹⁰⁷.

Local tissue immunosurveillance is of extreme importance to constrain early tumor development. Increased understanding of tissue-resident cells would allow the design of specific anti-tumor therapeutics for tumor eradication and long-term protection. The dynamic and temporal regulation of circulating and resident lymphocytes has opened new models to help us envisage how immune cells communicate with epithelia, neurons and stromal cells in tissues and coordinate regional and systemic remodelling in response to local perturbations.

Conclusions

Tissue-resident cells are highly abundant throughout the body. They have been generally considered to be a static population. More recent evidence makes it clear that these cells can sense changes in the environment and implement new programs that allow these cells to move, either locally, or even enter the circulatory system to re-join trafficking immune cells, at least for a short while. At present, we have only a

superficial understanding of these regulatory mechanisms. Although being tethered within a tissue offers a strong capacity to effect immunosurveillance, how we can target them therapeutically and deliver precise signals to optimize the positive effector activity of resident immune cells is not clear. Understanding the rules around this pathway offers significant opportunity for vaccine delivery and amplification of engineered cells (for example, chimeric antigen receptor T cells) to target particular tissues.

Key questions remain:

- What does heterogeneity of tissue-resident cells indicate—do they have enhanced or diminished protective functions?
- How can short-lived resident memory cells be modulated to enhance their long-term value for enhancement of barrier protection and thus potential for vaccination or anti-tumor responses at these surfaces?

- While tissue-resident cells are mainly thought to protect barriers, do they impede vaccine or anti-tumor targeting?
- How do we dampen down exuberant tissue-resident responses to prevent disease?
- How are tissue-resident cell numbers regulated? Is this niche-dependent and can tissue-resident cells be amplified to fill niches, or is the number of tissue-resident cells finite and defined homeostatically?

Although the categorization of immune cells as tissue-resident has only recently occurred, this understanding of a dedicated population with properties specific to barrier protection potentially opens many doors to therapeutic targeting and a reassessment of our approaches and previous failures. Future research will undoubtedly uncover new and tangible approaches that might be readily implemented and have immediate impact on treatment and prevention of disease.

References

- Mueller SN, Mackay LK: **Tissue-resident memory T cells: Local specialists in immune defence.** *Nat Rev Immunol.* 2016; **16**(2): 79–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
- Park SL, Zaid A, Hor JL, *et al.*: **Local proliferation maintains a stable pool of tissue-resident memory T cells after antiviral recall responses.** *Nat Immunol.* 2018; **19**(2): 183–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
- Wakim LM, Waithman J, van Rooijen N, *et al.*: **Dendritic cell-induced memory T cell activation in nonlymphoid tissues.** *Science.* 2008; **319**(5860): 198–202.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
- Beura LK, Wijeyesinghe S, Thompson EA, *et al.*: **T Cells in Nonlymphoid Tissues Give Rise to Lymph-Node-Resident Memory T Cells.** *Immunity.* 2018; **48**(2): 327–338.e5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
- Davies B, Prier JE, Jones CM, *et al.*: **Cutting Edge: Tissue-Resident Memory T Cells Generated by Multiple Immunizations or Localized Deposition Provide Enhanced Immunity.** *J Immunol.* 2017; **198**(6): 2233–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gebhardt T, Whitney PG, Zaid A, *et al.*: **Different patterns of peripheral migration by memory CD4⁺ and CD8⁺ T cells.** *Nature.* 2011; **477**(7363): 216–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
- Mackay LK, Stock AT, Ma JZ, *et al.*: **Long-lived epithelial immunity by tissue-resident memory T (T_{RM}) cells in the absence of persisting local antigen presentation.** *Proc Natl Acad Sci U S A.* 2012; **109**(18): 7037–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
- Steinert EM, Schenkel JM, Fraser KA, *et al.*: **Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance.** *Cell.* 2015; **161**(4): 737–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
- Gerlach C, Moseman EA, Loughhead SM, *et al.*: **The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis.** *Immunity.* 2016; **45**(6): 1270–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
- Osborn JF, Mooster JL, Hobbs SJ, *et al.*: **Enzymatic synthesis of core 2 O-glycans governs the tissue-trafficking potential of memory CD8⁺ T cells.** *Sci Immunol.* 2017; **2**(16): eaan6049.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
- Fonseca R, Beura LK, Quarnstrom CF, *et al.*: **Developmental plasticity allows outside-in immune responses by resident memory T cells.** *Nat Immunol.* 2020; **21**(4): 412–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
- Butcher EC, Picker LJ: **Lymphocyte Homing and Homeostasis.** *Science.* 1996; **272**(5258): 60–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dogra P, Rancan C, Ma W, *et al.*: **Tissue Determinants of Human NK Cell Development, Function, and Residence.** *Cell.* 2020; **180**(4): 749–763.e13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
- Teijaro JR, Turner D, Pham Q, *et al.*: **Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection.** *J Immunol.* 2011; **187**(11): 5510–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Channappanavar R, Zhao J, Perlman S: **T cell-mediated immune response to respiratory coronaviruses.** *Immunol Res.* 2014; **59**(1–3): 118–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Channappanavar R, Fett C, Zhao J, *et al.*: **Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.** *J Virol.* 2014; **88**(19): 11034–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wilk MM, Misiak A, McManus RM, *et al.*: **Lung CD4 Tissue-Resident Memory T Cells Mediate Adaptive Immunity Induced by Previous Infection of Mice with *Bordetella pertussis*.** *J Immunol.* 2017; **199**(1): 233–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Thawer SG, Horsnell WGC, Darby M, *et al.*: **Lung-resident CD4⁺ T cells are sufficient for IL-4R α -dependent recall immunity to *Nippostrongylus brasiliensis* infection.** *Mucosal Immunol.* 2014; **7**(2): 239–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Wilk MM, Mills KHG: **CD4 T_{RM} Cells Following Infection and Immunization: Implications for More Effective Vaccine Design.** *Front Immunol.* 2018; **9**: 1860.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Takamura S: **Persistence in Temporary Lung Niches: A Survival Strategy of Lung-Resident Memory CD8⁺ T Cells.** *Viral Immunol.* 2017; **30**(6): 438–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

21. Zens KD, Chen JK, Farber DL: **Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection.** *JCI Insight*. 2016; 1(10): e85832.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Zhao J, Zhao J, Mangalam AK, *et al.*: **Airway Memory CD4⁺ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.** *Immunity*. 2016; 44(6): 1379–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Flórido M, Muflihah H, Lin LCW, *et al.*: **Pulmonary immunization with a recombinant influenza A virus vaccine induces lung-resident CD4⁺ memory T cells that are associated with protection against tuberculosis.** *Mucosal Immunol*. 2018; 11(6): 1743–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
24. Morabito KM, Ruckwardt TJ, Bar-Haim E, *et al.*: **Memory Inflation Drives Tissue-Resident Memory CD8⁺ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus.** *Front Immunol*. 2018; 9: 1861.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
25. Si Y, Wen Y, Kelly SH, *et al.*: **Intranasal delivery of adjuvant-free peptide nanofibers elicits resident CD8⁺ T cell responses.** *J Control Release*. 2018; 282: 120–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
26. Szabo PA, Miron M, Farber DL: **Location, location, location: Tissue resident memory T cells in mice and humans.** *Sci Immunol*. 2019; 4(34): eaas9673.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Turner DL, Goldklang M, Cvetkovski F, *et al.*: **Biased Generation and In Situ Activation of Lung Tissue-Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma.** *J Immunol*. 2018; 200(5): 1561–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
28. Nguyen QP, Deng TZ, Witherden DA, *et al.*: **Origins of CD4⁺ circulating and tissue-resident memory T-cells.** *Immunology*. 2019; 157(1): 3–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Ely KH, Cookenham T, Roberts AD, *et al.*: **Memory T cell populations in the lung airways are maintained by continual recruitment.** *J Immunol*. 2006; 176(1): 537–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Niedzielska M, Israelsson E, Angermann B, *et al.*: **Differential gene expression in human tissue resident regulatory T cells from lung, colon, and blood.** *Oncotarget*. 2018; 9(90): 36166–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
31. Topham DJ, Reilly EC: **Tissue-Resident Memory CD8⁺ T Cells: From Phenotype to Function.** *Front Immunol*. 2018; 9: 515.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Li W, Gauthier JM, Higashikubo R, *et al.*: **Bronchus-associated lymphoid tissue-resident Foxp3⁺ T lymphocytes prevent antibody-mediated lung rejection.** *J Clin Invest*. 2019; 129(2): 556–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
33. Skon CN, Lee JY, Anderson KG, *et al.*: **Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8⁺ T cells.** *Nat Immunol*. 2013; 14(12): 1285–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
34. Mackay LK, Wynne-Jones E, Freestone D, *et al.*: **T-box Transcription Factors Combine with the Cytokines TGF- β and IL-15 to Control Tissue-Resident Memory T Cell Fate.** *Immunity*. 2015; 43(6): 1101–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Mackay LK, Minnich M, Kragten NAM, *et al.*: **Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes.** *Science*. 2016; 352(6284): 459–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
36. Behr FM, Kragten NAM, Wesselink TH, *et al.*: **Blimp-1 Rather Than Hobit Drives the Formation of Tissue-Resident Memory CD8⁺ T Cells in the Lungs.** *Front Immunol*. 2019; 10: 400.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
37. Oja AE, Vieira Braga FA, Remmerswaal EBM, *et al.*: **The Transcription Factor Hobit Identifies Human Cytotoxic CD4⁺ T Cells.** *Front Immunol*. 2017; 8: 325.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Stelma F, de Niet A, Sinnige MJ, *et al.*: **Human intrahepatic CD69⁺ CD8⁺ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity.** *Sci Rep*. 2017; 7(1): 6172.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Schneider C, Lee J, Koga S, *et al.*: **Tissue-Resident Group 2 Innate Lymphoid Cells Differentiate by Layered Ontogeny and In Situ Perinatal Priming.** *Immunity*. 2019; 50(6): 1425–1438.e5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
40. Liu Z, Gu Y, Chakarov S, *et al.*: **Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived Cells.** *Cell*. 2019; 178(6): 1509–1525.e19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
41. Smith NL, Patel RK, Reynaldi A, *et al.*: **Developmental Origin Governs CD8⁺ T Cell Fate Decisions during Infection.** *Cell*. 2018; 174(1): 117–130.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
42. Bian Z, Gong Y, Huang T, *et al.*: **Deciphering human macrophage development at single-cell resolution.** *Nature*. 2020; 582(7813): 571–576.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
43. Bando JK, Liang HE, Locksley RM: **Identification and distribution of developing innate lymphoid cells in the fetal mouse intestine.** *Nat Immunol*. 2015; 16(2): 153–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Masopust D, Vezyz V, Marzo AL, *et al.*: **Preferential localization of effector memory cells in nonlymphoid tissue.** *Science*. 2001; 291(5512): 2413–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Marshall DR, Turner SJ, Belz GT, *et al.*: **Measuring the diaspora for virus-specific CD8⁺ T cells.** *Proc Natl Acad Sci U S A*. 2001; 98(11): 6313–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Masopust D, Choo D, Vezyz V, *et al.*: **Dynamic T cell migration program provides resident memory within intestinal epithelium.** *J Exp Med*. 2010; 207(3): 553–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
47. Gebhardt T, Wakim LM, Eidsmo L, *et al.*: **Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus.** *Nat Immunol*. 2009; 10(5): 524–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
48. van de Pavert SA, Olivier BJ, Goverse G, *et al.*: **Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation.** *Nat Immunol*. 2009; 10(11): 1193–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
49. Sawa S, Lochner M, Satoh-Takayama N, *et al.*: **ROR γ t⁺ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota.** *Nat Immunol*. 2011; 12(4): 320–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
50. Constantinides MG, McDonald BD, Verhoef PA, *et al.*: **A committed precursor to innate lymphoid cells.** *Nature*. 2014; 508(7496): 397–401.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
51. Cherrier M, Sawa S, Eberl G: **Notch, Id2, and ROR γ t sequentially orchestrate the fetal development of lymphoid tissue inducer cells.** *J Exp Med*. 2012; 209(4): 729–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Shiow LR, Rosen DB, Brdicová N, *et al.*: **CD69 acts downstream of interferon- α/β to inhibit S1P₁ and lymphocyte egress from lymphoid organs.** *Nature*. 2006; 440(7083): 540–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
53. Cheuk S, Schlums H, Gallais Séréral I, *et al.*: **CD49a Expression Defines Tissue-Resident CD8⁺ T Cells Poised for Cytotoxic Function in Human Skin.** *Immunity*. 2017; 46(2): 287–300.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
54. Fuchs A, Vermi W, Lee JS, *et al.*: **Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12⁺ and IL-15-Responsive IFN- γ -Producing Cells.** *Immunity*. 2013; 38(4): 769–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Gury-BenAri M, Thaïs CA, Serafini N, *et al.*: **The Spectrum and Regulatory Landscape of Intestinal Innate Lymphoid Cells Are Shaped by the Microbiome.** *Cell*. 2016; 166(5): 1231–1246.e13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
56. Bar-Ephraim YE, Koning JJ, Burniol Ruiz E, *et al.*: **CD62L Is a Functional and Phenotypic Marker for Circulating Innate Lymphoid Cell Precursors.** *J Immunol*. 2018; 202(1): 171–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
57. Lim AI, Li Y, Lopez-Lastra S, *et al.*: **Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation.** *Cell*. 2017; 168(6): 1086–1100.e10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
58. Fang V, Chaluvadi VS, Ramos-Perez WD, *et al.*: **Gradients of the signaling lipid S1P in lymph nodes position natural killer cells and regulate their interferon- γ response.** *Nat Immunol*. 2017; 18(1): 15–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
59. Jenne CN, Enders A, Rivera R, *et al.*: **T-bet-dependent S1P₂ expression in NK cells promotes egress from lymph nodes and bone marrow.** *J Exp Med*. 2009; 206(11): 2469–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

60. Huang Y, Mao K, Chen X, *et al.*: **S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense.** *Science*. 2018; 359(6371): 114–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
61. Ricardo-Gonzalez RR, Schneider C, Liao C, *et al.*: **Tissue-specific pathways extrude activated ILC2s to disseminate type 2 immunity.** *J Exp Med*. 2020; 217(4): e20191172.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
62. Stier MT, Zhang J, Goleniewska K, *et al.*: **IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow.** *J Exp Med*. 2018; 215(1): 263–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
63. Karta MR, Rosenthal PS, Beppu A, *et al.*: **β_2 integrins rather than β_1 integrins mediate *Alternaria*-induced group 2 innate lymphoid cell trafficking to the lung.** *J Allergy Clin Immunol*. 2018; 141(1): 329–338.e12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
64. Emgård J, Kammoun H, García-Cassani B, *et al.*: **Oxysterol Sensing through the Receptor GPR183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation.** *Immunity*. 2018; 48(1): 120–132.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
65. Chu C, Moriyama S, Li Z, *et al.*: **Anti-microbial Functions of Group 3 Innate Lymphoid Cells in Gut-Associated Lymphoid Tissues Are Regulated by G-Protein-Coupled Receptor 183.** *Cell Rep*. 2018; 23(13): 3750–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
66. Wyss A, Raselli T, Perkins N, *et al.*: **The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis.** *Mucosal Immunol*. 2019; 12(3): 733–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
67. Sawada M, Itoh Y, Suzumura A, *et al.*: **Expression of cytokine receptors in cultured neuronal and glial cells.** *Neurosci Lett*. 1993; 160(2): 131–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Neumann H, Schweigreiter R, Yamashita T, *et al.*: **Tumor Necrosis Factor Inhibits Neurite Outgrowth and Branching of Hippocampal Neurons by a Rho-Dependent Mechanism.** *J Neurosci*. 2002; 22(3): 854–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Gougeon PY, Lourenssen S, Han TY, *et al.*: **The pro-inflammatory cytokines IL-1 β and TNF α are neurotrophic for enteric neurons.** *J Neurosci*. 2013; 33(8): 3339–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Klose CSN, Mahlaköiv T, Moeller JB, *et al.*: **The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation.** *Nature*. 2017; 549(7671): 282–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
71. Cardoso V, Chesné J, Ribeiro H, *et al.*: **Neuronal regulation of type 2 innate lymphoid cells via neuromedin U.** *Nature*. 2017; 549(7671): 277–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
72. Wallrapp A, Riesenfeld SJ, Burkett PR, *et al.*: **The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation.** *Nature*. 2017; 549(7672): 351–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
73. Said SI, Rosenberg RN: **Vasoactive intestinal polypeptide: Abundant immunoreactivity in neural cell lines and normal nervous tissue.** *Science*. 1976; 192(4242): 907–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Nussbaum JC, van Dyken SJ, von Moltke J, *et al.*: **Type 2 innate lymphoid cells control eosinophil homeostasis.** *Nature*. 2013; 502(7470): 245–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
75. Talbot J, Bianchini FJ, Nascimento DC, *et al.*: **CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis.** *Arthritis Rheumatol*. 2015; 67(7): 1751–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Seillet C, Luong K, Tellier J, *et al.*: **The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity.** *Nat Immunol*. 2020; 21(2): 168–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Talbot J, Hahn P, Kroehling L, *et al.*: **Feeding-dependent VIP neuron-ILC3 circuit regulates the intestinal barrier.** *Nature*. 2020; 579(7800): 575–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
78. Moriyama S, Brestoff JR, Flamar AL, *et al.*: **β_2 -adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses.** *Science*. 2018; 359(6379): 1056–61.
[Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
79. Borovikova LV, Ivanova S, Zhang M, *et al.*: **Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.** *Nature*. 2000; 405(6785): 458–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Dalil J, Colas RA, Arnardottir H, *et al.*: **Vagal Regulation of Group 3 Innate Lymphoid Cells and the Immunoresolvent PCTRI Controls Infection Resolution.** *Immunity*. 2017; 46(1): 92–105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Zitvogel L, Tesniere A, Kroemer G: **Cancer despite immunosurveillance: Immunoselection and immunosubversion.** *Nat Rev Immunol*. 2006; 6(10): 715–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Vesely MD, Kershaw MH, Schreiber RD, *et al.*: **Natural innate and adaptive immunity to cancer.** *Annu Rev Immunol*. 2011; 29: 235–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Hanahan D, Weinberg RA: **Hallmarks of Cancer: The Next Generation.** *Cell*. 2011; 144(5): 646–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
84. Björklund AK, Forkel M, Picelli S, *et al.*: **The heterogeneity of human CD127⁺ innate lymphoid cells revealed by single-cell RNA sequencing.** *Nat Immunol*. 2016; 17(4): 451–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Han X, Zhou Z, Fei L, *et al.*: **Construction of a human cell landscape at single-cell level.** *Nature*. 2020; 581(7808): 303–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
86. Guo X, Zhang Y, Zheng L, *et al.*: **Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing.** *Nat Med*. 2018; 24(7): 978–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Szabo PA, Levitin HM, Miron M, *et al.*: **Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease.** *Nat Commun*. 2019; 10(1): 4706.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
88. Savas P, Virassamy B, Ye C, *et al.*: **Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.** *Nat Med*. 2018; 24(7): 986–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
89. Wang B, Wu S, Zeng H, *et al.*: **CD103⁺ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.** *J Urol*. 2015; 194(2): 556–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Djenidi F, Adam J, Goubar A, *et al.*: **CD8⁺ CD103⁺ Tumor-Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients.** *J Immunol*. 2015; 194(7): 3475–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Ganesan AP, Clarke J, Wood O, *et al.*: **Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.** *Nat Immunol*. 2017; 18(8): 940–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. Koh J, Kim S, Kim MY, *et al.*: **Prognostic implications of intratumoral CD103⁺ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.** *Oncotarget*. 2017; 8(8): 13762–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. Webb JR, Milne K, Watson P, *et al.*: **Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer.** *Clin Cancer Res*. 2014; 20(2): 434–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Edwards J, Wilmott JS, Madore J, *et al.*: **CD103⁺ Tumor-Resident CD8⁺ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment.** *Clin Cancer Res*. 2018; 24(13): 3036–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
95. Nizard M, Roussel H, Diniz MO, *et al.*: **Induction of resident memory T cells enhances the efficacy of cancer vaccine.** *Nat Commun*. 2017; 8: 198.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
96. Nizard M, Roussel H, Tartour E: **Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines.** *Clin Cancer Res*. 2016; 22(3): 530–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Park SL, Buzzai A, Rautela J, *et al.*: **Tissue-resident memory CD8⁺ T cells promote melanoma-immune equilibrium in skin.** *Nature*. 2019; 565(7739): 366–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Faculty Opinions Recommendation](#)
98. Boddupalli CS, Bar N, Kadaveru K, *et al.*: **Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident**

- memory T cells. *JCI Insight*. 2016; 1(21): e88955.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. Clarke J, Panwar B, Madrigal A, *et al.*: **Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer.** *J Exp Med*. 2019; 216(9): 2128–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
 100. Tumino N, Vacca P, Quatrini L, *et al.*: **Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?** *Front Immunol*. 2019; 10: 3140.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 101. Chiossone L, Dumas PY, Vienne M, *et al.*: **Natural killer cells and other innate lymphoid cells in cancer.** *Nat Rev Immunol*. 2018; 18(11): 671–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
 102. An Z, Flores-Borja F, Irshad S, *et al.*: **Pleiotropic Role and Bidirectional Immunomodulation of Innate Lymphoid Cells in Cancer.** *Front Immunol*. 2019; 10: 3111.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 103. Ducimetière L, Vermeer M, Tugues S: **The Interplay Between Innate Lymphoid Cells and the Tumor Microenvironment.** *Front Immunol*. 2019; 10: 2895.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)
 104. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, *et al.*: **Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.** *Nat Immunol*. 2017; 18(9): 1004–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
 105. Trabanelli S, Chevalier MF, Martinez-Usatorre A, *et al.*: **Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.** *Nat Commun*. 2017; 8(1): 593.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 106. Ercolano G, Falquet M, Vanoni G, *et al.*: **ILC2s: New Actors in Tumor Immunity.** *Front Immunol*. 2019; 10: 2801.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 107. Moral JA, Leung J, Rojas LA, *et al.*: **ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.** *Nature*. 2020; 579(7797): 130–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [Faculty Opinions Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Jeffrey C. Nolz**

Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA

Competing Interests: No competing interests were disclosed.

2. **Kingston Mills**

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland

Competing Interests: No competing interests were disclosed.

3. **Richard M. Locksley**

Howard Hughes Medical Institute, Department of Medicine, University of California, San Francisco, CA, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research